About

Dr. Aniruddha (Anu) Hazra is an Associate Professor in the Section of Infectious Diseases and Global Health at the University of Chicago. He serves as the Director of STI Services at the Chicago Center of HIV Elimination and is also the director of the University's Infectious Diseases Fellowship Program. His clinical and research interests focus on sexually transmitted infections and their impact on sexual and gender minorities, as well as other vulnerable populations living on the South Side of Chicago. His work encompasses complex HIV management, PrEP care, hepatitis C management, gender-affirming hormone therapy, high-resolution anoscopy, treatment of opioid use disorder, and medical education. Dr. Hazra is committed to equitable healthcare delivery to LGBTQ+ individuals of color and has been involved in initiatives such as CDC's Let Stop HIV Together Campaign. He works at Howard Brown Health, the largest LGBTQ+ health provider in the country, and has a background that includes training at Beth Israel Deaconess Medical Center, Rush University Medical Center, and Boston University School of Medicine.

Research topics

• Medicine
• Internal medicine
• Family medicine
• Virology
• Demography
• Biology
• Surgery
• Pediatrics
• Gerontology
• Nursing
• Intensive care medicine
• Genetics
• Immunology

Selected publications

• Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis

  Advances in Therapy · 2026-05-22

  articleOpen access

  INTRODUCTION: Long-acting injectable cabotegravir (hereafter referred to as cabotegravir) is the first long-acting injectable approved for pre-exposure prophylaxis (PrEP) based on the HPTN 083 and 084 trials. Long-acting injectable lenacapavir (hereafter referred to as lenacapavir) was approved for PrEP based on the PURPOSE 1 and 2 trials. In the absence of a head-to-head trial, we conducted an indirect treatment comparison (ITC) to assess efficacy of lenacapavir versus cabotegravir in reducing the risk of HIV acquisition. METHODS: A systematic literature review identified all relevant trials. Efficacy inputs for this ITC were derived from re-adjudicated data from the injection phase of the HPTN trials or published data from the PURPOSE trials. The ITC was performed using 2 network approaches: (1) using no PrEP and (2) using daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as common comparators, with adjustments accounting for differing levels of adherence to TDF/FTC across trials. Sensitivity analyses were also performed using data from both the oral lead-in and injection phases of the HPTN trials. RESULTS: Both network approaches estimated high and comparable efficacy of cabotegravir and lenacapavir. Using no PrEP (network approach 1), the base case estimated hazard ratio (95% CrI) of lenacapavir versus cabotegravir was 1.04 (0.19, 5.69) in men who have sex with men and transgender women and 0.00 (0.00, 3.21) in cisgender women. Predicted efficacy (95% CrI) rates of cabotegravir versus no PrEP were high in men who have sex with men and transgender women 96% (90%, 98%)] and cisgender women [98% (89%, 100%)] in the HPTN trials, which were comparable to the PURPOSE trials [men and gender-diverse people, 96% (82%, 99%); cisgender women, 100%(96%,100%)]. Sensitivity analyses confirmed these findings. CONCLUSION: Based on this ITC, cabotegravir and lenacapavir offer similar and high efficacy in preventing HIV acquisitions compared with no PrEP or TDF/FTC. Graphical abstract and video abstract available for this article.

  PublisherOA PDFDOI

• <b>Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis</b>

  Figshare · 2026-05-06

  articleOpen access

  <b>Article full text</b> The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above graphical abstract and video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).

  PublisherDOI

• The safety and tolerability of oral TDF/FTC as pre-exposure prophylaxis among men who have sex with men in China: a prospective cohort study

  BMC Infectious Diseases · 2026-05-21

  articleOpen access

  BACKGROUND: Pre-exposure prophylaxis (PrEP) has been demonstrated as an effective strategy for preventing HIV infection. However, multiple barriers contribute to its suboptimal uptake in China, with drug safety being a shared concern for both clinicians and patients. This study aimed to assess the safety and tolerability of oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for PrEP in a real-world setting in China. METHODS: An open-label, prospective cohort study was conducted between September 2021 and September 2024 in Wuhan and Guangzhou, China. PrEP-eligible men who have sex with men (MSM) were enrolled, participants were prescribed TDF/FTC as PrEP and followed up for 12 months. Adverse events (AEs) were self-reported, and participants underwent regular monitoring for HIV, syphilis, liver and kidney function during follow-up. RESULTS: A total of 1,138 participants enrolled and initiated PrEP, with 1,045 completing at least one follow-up visit. Seven participants were diagnosed with HIV infection, yielding an HIV incidence rate of 0.8 per 100 person-years (95% CI: 0.2-1.4). A total of 62 participants self-reported 106 AEs, the majority of which were grade 1, with no serious AEs observed. Participants reported a significantly higher AE incidence with daily PrEP than on-demand PrEP (14.7 per 100 person-years vs. 9.3 per 100 person-years, P < 0.05). Additionally, 128 episodes of serum creatinine (SCr) and 701 episodes of liver enzyme abnormalities were recorded, and mild elevations in ALT, AST, and SCr were significantly more frequent among participants taking the daily regimen. Significant ALT elevations were observed from the 1st month to the 9th month follow-up, while SCr elevations occurred predominantly in the 1st month. CONCLUSIONS: Both daily and on-demand PrEP regimens with TDF/FTC are safe and well tolerated for the prevention of HIV among Chinese MSM. On-demand PrEP with fewer AEs and comparable effectiveness provides an alternative HIV prevention strategy for Chinese MSM in real-world settings. TRIAL REGISTRATION: The study is registered in Clinical Trial databases in China (ChiCTR2100048981, July 19, 2021) and the US (NCT04754139, February 11, 2021).

  PublisherDOI

• Anal Cancer Screening Prevalence in U.S. Cities and Factors Associated With Screening

  American Journal of Preventive Medicine · 2026-04-10

  articleOpen accessSenior author
  PublisherOA PDFDOI

• Detectable coronary artery score among people living with HIV with regional, study and population variations: a systematic review and meta-analysis

  JAIDS Journal of Acquired Immune Deficiency Syndromes · 2026-03-20

  articleSenior author

  BACKGROUND: People living with HIV (PLWH) have a higher risk of coronary artery disease, partly due to chronic inflammation and antiretroviral therapy-related effects. Coronary artery calcium (CAC) scoring is a non-invasive marker of subclinical atherosclerosis and cardiovascular risk. Previous reviews reported high CAC prevalence in PLWH but lacked data on severity and regional or population-specific differences. METHODS: Systematic review and meta-analysis of records published before April 15, 2025, reporting the pooled percentage of PLWH with detectable CAC (CAC > 0), mild CAC (CAC 1-99), moderate CAC (CAC 100-400) and severe CAC (CAC >400). Subgroup analyses explored variation by region, study design, and population characteristics. RESULTS: Fifty-three records were included; 31 contributed to the meta-analysis. The pooled prevalence of detectable CAC was 43.6% (95% CI: 39.1-48.1), with high heterogeneity (I2 = 91%). Percentage of detectable CAC among PLWH was highest in North America (46.6%) and lowest in Africa (14.1%) and among general adult PLWH (55.8%) and less among those on ART (34.5%). The percentage of PLWH with detectable CAC was higher among cross sectional studies (44.2%) and prospective cohorts (43.3%) in comparison to clinical trials (35.5%). Regarding severity of CAC among PLWH, 27.6% had mild CAC, 10.8% moderate, and 5.1% severe CAC. No significant publication bias was detected. CONCLUSIONS: Nearly half of PLWH have detectable CAC, with substantial regional and population-level differences. These findings highlight the need for targeted cardiovascular screening strategies in PLWH and support further research into the clinical utility of CAC scoring to guide preventive therapy.

  PublisherDOI

• <b>Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis</b>

  Figshare · 2026-05-06

  articleOpen access

  <b>Article full text</b> The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above graphical abstract and video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).

  PublisherDOI

• Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis

  Clinical Infectious Diseases · 2026-05-14

  article1st authorCorresponding

  Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable clinical and structural barriers to early persistence.

  PublisherDOI

• HIV diagnosis following psychiatric hospitalization among a large cohort of privately-insured people in the United States, 2003–2024

  General Hospital Psychiatry · 2026-04-19

  articleSenior author
  PublisherDOI

• Distinguishing patients with suspected auto- versus allo-anti-Jka antibodies and highlighting the clinical significance: A case series from India

  Transfusion and Apheresis Science · 2026-03-10 · 1 citations

  article
  PublisherDOI

• A Co-Created Digital Intervention to Improve Oral PrEP Adherence Among Men Who Have Sex with Men in China: A Stepped-Wedge Randomized Trial in China

  SSRN Electronic Journal · 2026-01-01

  preprintOpen access
  PublisherDOI

Frequent coauthors

• Samuel R. Bunting

  University of Chicago

  17 shared

• John A. Schneider

  University of Chicago

  16 shared

• Brian A. Feinstein

  Rosalind Franklin University of Medicine and Science

  13 shared

• Jean‐Michel Molina

  12 shared

• Chloe Orkin

  Royal London Hospital

  11 shared

• Sharon Walmsley

  University of Toronto

  10 shared

• Kimberly A. Stanford

  University of Chicago

  10 shared

• José Luís Blanco

  10 shared

Labs

• Aniruddha Hazra LabPI

Education

• B.A., Biochemistry & Molecular Biology; African Studies

  Boston University

  2008

• M.D.

  Boston University School of Medicine

  2012

• M.D., Infectious Diseases Fellowship

  Beth Israel Deaconess Medical Center

  2018

• M.D., Internal Medicine Residency

  Rush University Medical Center

  2015

• M.D., Chief Resident

  Rush University Medical Center

  2016